HER2-low breast cancer: Evolution from primary breast cancer to relapse

被引：3
|
作者：
Miglietta, F. [1 ]
Griguolo, G. [1 ]
Bottosso, M. [1 ]
Giarratano, T. [2 ]
Lo Mele, M. [3 ]
Fassan, M. [4 ]
Cacciatore, M. [5 ]
Genovesi, E. [1 ]
De Bartolo, D. [4 ]
Vernaci, G. [2 ]
Conte, P. F. [1 ]
Guarneri, V. [1 ]
Dieci, M. V. [1 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol DISCOG, Padua, Italy
[2] Ist Oncol Veneto IRCCS, Dipartimento Oncol 2, Padua, Italy
[3] Univ Hosp Padua, Surg Pathol Unit, Padua, Italy
[4] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, Italy
[5] Treviso Gen Hosp, Dept Pathol & Mol Genet, Treviso, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.03.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4MO_PR
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [1] Evolution of HER2-low expression from primary to recurrent breast cancer
    Federica Miglietta
    Gaia Griguolo
    Michele Bottosso
    Tommaso Giarratano
    Marcello Lo Mele
    Matteo Fassan
    Matilde Cacciatore
    Elisa Genovesi
    Debora De Bartolo
    Grazia Vernaci
    Ottavia Amato
    PierFranco Conte
    Valentina Guarneri
    Maria Vittoria Dieci
    npj Breast Cancer, 7
  • [2] HER2-Low expression in primary male breast cancer
    Rudlowski, Christian
    Erices-Leclercq, Melanie
    Nobbe, Katleen
    Baldus, Stephan
    Foerster, Robert
    Foerster, Frank
    Lubig, Sabine
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 29 - 29
  • [3] HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
    Mengyuan Cai
    Ming Li
    Hong Lv
    Shuling Zhou
    Xiaoli Xu
    Ruohong Shui
    Wentao Yang
    BMC Cancer, 23
  • [4] HER2-Low Breast Cancer: Evolution of HER2 expression from Primary Tumor to Distant Metastases
    Cai, Mengyuan
    Li, Ming
    Lv, Hong
    Zhou, Shuling
    Xu, Xiaoli
    Shui, Ruohong
    Yang, Wentao
    LABORATORY INVESTIGATION, 2023, 103 (03) : S107 - S109
  • [5] HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
    Cai, Mengyuan
    Li, Ming
    Lv, Hong
    Zhou, Shuling
    Xu, Xiaoli
    Shui, Ruohong
    Yang, Wentao
    BMC CANCER, 2023, 23 (01)
  • [6] Evolution of HER2-low expression from primary to recurrent breast cancer (vol 7, 149, 2021)
    Miglietta, Federica
    Griguolo, Gaia
    Bottosso, Michele
    Giarratano, Tommaso
    Lo Mele, Marcello
    Fassan, Matteo
    Cacciatore, Matilde
    Genovesi, Elisa
    De Bartolo, Debora
    Vernaci, Grazia
    Amato, Ottavia
    Conte, PierFranco
    Guarneri, Valentina
    Dieci, Maria Vittoria
    NPJ BREAST CANCER, 2021, 7 (01)
  • [7] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Schnog, John-John B.
    Samson, Michael J.
    Duits, Ashley J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1143 - 1144
  • [8] Biology and Treatment of HER2-Low Breast Cancer
    Nicolo, Eleonora
    Tarantino, Paolo
    Curigliano, Giuseppe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 117 - 132
  • [9] HER2-Low Breast Cancer: a New Subtype?
    Chiara Corti
    Federica Giugliano
    Eleonora Nicolò
    Paolo Tarantino
    Carmen Criscitiello
    Giuseppe Curigliano
    Current Treatment Options in Oncology, 2023, 24 : 468 - 478
  • [10] Clinical Significance of HER2-low Breast Cancer
    Zaiem, Fadi
    AbuJamea, Asem
    Kheil, Mira
    Numi, Anna
    Abbas, Omar
    Awada, Sanaa
    Almsaddi, Ragad
    Al-Juburi, Saleh
    Larson, Lauren
    Jain, Deepti
    AlSaghir, Maya
    Jang, Hyejeong
    Kim, Seongho
    Bandyopadhyay, Sudeshna
    Jaiman, Sunil
    Ali-Fehmi, Rouba
    CANCER RESEARCH, 2024, 84 (09)
12345